Loading company
Hemab Therapeutics Holdings, Inc.
COAG · Nasdaq · ·
Next earnings: November 10, 2026
$32.67-1.4%Sep 29 close
- 1M
- -25.8%
COAG · Nasdaq · ·
Next earnings: November 10, 2026
$32.67-1.4%Sep 29 close
Hemab Therapeutics Holdings, Inc. is scheduled to report next on November 10, 2026. The date comes from Nasdaq’s earnings calendar, and companies sometimes move it.
From the company’s own 8-K filing.
Releases land after the close or before the open, so the move is the session that follows.
Glanzmann thrombasthenia (GT) is a severe bleeding disorder marked by debilitating, sometimes life-threatening bleeding episodes. Results from an international natural history study (Glanzmann’s 360) revealed the substantial burden of this disease: 88% of the 117 participants reported at least one bleed in the previous week with 65% requiring a bleed-related hospital visit in the prior six months. These bleeding episodes significantly impacted patients’ mental health and quality of life, with over 80% having missed work or school, over 50% facing limitations in attending social events, and over 50% experiencing restrictions in travel. To date, there are no approved prophylactic treatment options for GT.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Hemab Therapeutics Holdings, Inc.’s Item 2.02 8-K filed August 11, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
Hemab Therapeutics Holdings, Inc. has no earnings call transcript available.